Core Insights - A milestone solution for infant vascular tumor treatment has been launched in China, with the modified new drug, Malate Timolol Gel (brand name: Beimeijing), developed by Beijing Melson Pharmaceutical Technology Co., Ltd. after twelve years of research [1] - The drug is the first and only approved topical gel formulation for treating "proliferative superficial infantile hemangiomas," marking a significant advancement for China in this medical field [1] - Beimeijing has received national-level price certification, establishing a traceable and referenceable price benchmark for Chinese original research drugs in the international market [1] Industry Overview - Infantile hemangiomas are the most common benign tumors in infants in China, with a global incidence rate estimated between 5% and 12%, and superficial types accounting for nearly 70% [2] - The "golden window period" for effective intervention is within the first 1-6 months after birth, as failure to treat during this period can lead to permanent skin issues [2] - Traditional treatment methods have limitations in safety, convenience, and accessibility, highlighting the need for specialized topical medications [2] Product Development - Beimeijing's development was based on core patents from the team of Professor Zheng Jiawei at Shanghai Jiao Tong University School of Medicine, with a comprehensive approach from molecular design to clinical validation [2] - The gel formulation allows for localized application, minimizing systemic exposure risks and enhancing safety for infants, making it a more convenient and pain-free option compared to oral medications or surgical treatments [2] Clinical Efficacy - Phase III clinical trial data showed that among 121 infants aged 1-6 months, 60.7% achieved clinical cure (Grade IV improvement) after 24 weeks of treatment, with an overall efficacy rate of 89.4% and good safety profile [3] - The collaboration with Ali Health aims to create a comprehensive service ecosystem centered around the child, ensuring that the standardized treatment approach represented by Beimeijing reaches every family in need [3]

Core Insights - Alibaba Health and Beijing Meirsen Pharmaceutical Technology Development Co., Ltd. have formed a strategic partnership to collaborate in the field of innovative drugs for pediatric specialties, specifically focusing on the treatment of infantile hemangiomas with the drug Beimeijing (Timolol Maleate Gel) [1][2] Group 1: Product and Market Overview - Beimeijing is the world's first approved topical innovative drug for the treatment of proliferative superficial infantile hemangiomas, addressing a condition that affects an estimated 5% to 12% of infants globally, with superficial types accounting for nearly 70% of cases [1] - A meta-analysis by the Chinese Medical Association indicates that 25% to 69% of untreated children may experience long-term issues such as scarring and skin laxity, particularly affecting areas like the head and face, which can impact psychological health and social interactions [1] Group 2: Clinical Data and Efficacy - Phase III clinical trial results show that among 121 infants aged 1 to 6 months, 60.7% achieved clinical cure (Grade IV improvement) after 24 weeks of treatment, with an overall efficacy rate of 89.4%, demonstrating good safety and providing a new effective option for patients [1] Group 3: Strategic Initiatives and Future Plans - Beimeijing will be exclusively launched on Alibaba Health's platform on January 13, with plans to initiate the "Infant Hemangioma Care Program," which will integrate expert consultations, educational live streams, medication guidance communities, and public welfare projects to create a comprehensive care loop from awareness to recovery [2] - The collaboration aims to leverage Alibaba Health's ecosystem capabilities alongside Meirsen's expertise in pediatric specialty research, not only to provide a new drug but also to enhance health management solutions for children in China and promote industry standard upgrades [2] - Alibaba Health emphasizes that this strategic partnership is a key step in deepening its vertical disease management capabilities and implementing a patient-centered value strategy, aiming to maximize value through precise outreach, standardized treatment, and long-term management [2]